2023 World Conference on Lung Cancer (Posters)-P2.09. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)

P2.09. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

Pdf Summary

This study investigated the impact of TP53 (tumor protein 53) variants in patients with HER2/ERBB2-mutated non-small cell lung cancer (NSCLC). TP53 variants are common in NSCLC and have been associated with poor outcomes in EGFR-mutant NSCLC. However, their impact in HER2-mutated NSCLC is not well understood.<br /><br />The study included 82 patients with HER2-mutated NSCLC. TP53 status was examined and its associations with demographics and outcomes, including overall response, survival, progression-free survival, and recurrence-free survival, were analyzed.<br /><br />Co-mutations of TP53 and HER2 were found in 48% of the patients. There were no differences in demographics between the TP53-mutated and TP53 wildtype cohorts. The median progression-free survival was shorter in the TP53-mutated cohort compared to the wildtype cohort, although this difference was not statistically significant. The median recurrence-free survival and overall survival were also shorter in the TP53-mutated cohort, and these differences were statistically significant.<br /><br />There was a tendency for a higher incidence of brain metastases in patients with TP53 variants. Approximately one-third of the patients received targeted therapy as their first-line treatment.<br /><br />The study suggests that TP53 variants may predict a poor response to targeted treatments and are prognostic of shorter overall survival and progression-free survival in HER2-mutated NSCLC. The findings support the consideration of stratification by TP53 status in future treatment strategies.

Asset Subtitle

Jamie Feng

Meta Tag

Speaker Jamie Feng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

TP53 variants

HER2/ERBB2-mutated NSCLC

non-small cell lung cancer

EGFR-mutant NSCLC

overall response

survival

progression-free survival

recurrence-free survival

co-mutations

brain metastases